New Delhi: The central government’s Subject Expert Committee (SEC) is likely to meet on Wednesday on drugmaker Dr. Reddy’s application seeking emergency use authorisation for the Sputnik V vaccine in India. If the SEC gives a nod, Sputnik V will be India’s third vaccine after Covaxin and Covishield, News18 reported.
Dr. Reddy’s has partnered with the Sputnik V vaccine to run clinical trials in India. It had submitted the immunogenicity data after a meeting that was held on February 24.
Dr Reddy’s has partnered with Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India. The Russian vaccine has shown an efficacy of 91.6 %.
Comments are closed.